Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients - Centre François Baclesse Accéder directement au contenu
Article Dans Une Revue Blood Année : 2022

Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients

Stephanie Nguyen

Résumé

Three reports address the protection of the vulnerable population of patients with hematologic malignancies in the face of the ongoing COVID pandemic. The reports suggest that some patients who fail to mount a B-cell response to vaccine may nevertheless have protective T cell responses. As a group, these reports suggest that patients should continue to be immunized with additional doses to attempt to improve immune response but that they need to maintain the precautions recommended for the unvaccinated.

Domaines

Immunothérapie

Dates et versions

hal-03602166 , version 1 (08-03-2022)

Identifiants

Citer

Alexis Maillard, Rabah Redjoul, Marion Klemencie, Hélène Labussière Wallet, Amandine Le Bourgeois, et al.. Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients. Blood, 2022, 139 (1), pp.134-137. ⟨10.1182/blood.2021014232⟩. ⟨hal-03602166⟩
60 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More